BioLineRx Announces Publication of Pre-clinical Results Demonstrating Efficacy of BL-7010, an Oral Treatment for Celiac Disease and Gluten Sensitivity

Just last week BioLineRx, a biopharmaceutical development company announced successful pre-clinical testing of a potentially revolutionary treatment for celiac disease. This new treatment may help celiac disease patients reduce their gluten toxins to create an overall healthy body for all celiac disease patients.
Jerusalem, Israel – February 21, 2012 – BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced the publication of pre-clinical results demonstrating that BL-7010, an orally available treatment for celiac disease, reduces gluten toxicity (the negative effect of gluten on the patient’s body). The research was published in the February edition of Gastroenterology.
The findings indicate that BL-7010 (previously called P(HEMA-co-SS)) reduces digestion of wheat gluten, thereby decreasing its

In light of the recent article by Huffington Post entitled 
On a recent visit to a museum, my husband and I stopped at its cafeteria for a snack. The choices were cookies and cupcakes, pretzels and potato chips, and assorted drinks. Clearly, the cafeteria didn’t cater to those of us who are gluten-sensitive, lactose-intolerant, and/or weight watchers.


LEXINGTON, Mass., Dec. 13, 2011 /PRNewswire/ — Avaxia Biologics, Inc., a privately-held biotech company developing oral antibody drugs that act locally within the gastrointestinal tract, announced today that the company was awarded U.S. Patent 8,071,101, “Antibody Therapy for Treatment of Diseases Associated With Gluten Intolerance.”




